Overview: Homocystine (Plasma) TestIntroduction: The Homocystine (Plasma) Test tests homocystine levels to diagnose homocystinuria or cardiovascular risk, helping prevent heart disease or developmental issues. Affecting 1 in 200,000 people, homocystinuria poses diagnostic challenges due to varied symptoms. Following 2023 American Heart Association (AHA) guidelines, it uses LC-MS/MS for high accuracy, supporting biochemistry screening. This test is vital for diagnosis, prevention planning, and improving outcomes in cardiology and metabolism.
Other Names: Plasma Homocystine Test, Homocystinuria Risk Assay.
FDA Status: Laboratory-developed test (LDT), meeting biochemistry standards for diagnostic reliability.
Historical Milestone: Homocystine testing began in the 1960s with research by Carson, who linked it to homocystinuria. LC-MS/MS advancements in the 2000s by Agilent improved detection, surpassing earlier amino acid chromatography.
Purpose: Measures homocystine levels to diagnose homocystinuria or assess cardiovascular risk, guides vitamin B6 or folate therapy, and evaluates patients with heart disease risk, aiming to prevent complications.
Test Parameters: Homocystine levels
Pretest Condition: Fasting preferred to reflect baseline levels. Collect plasma. Report history of cardiovascular or developmental issues.
Specimen: Plasma (NaHep, 2-4 mL); 2 mL plasma in Na Heparin tube. Transport in a biohazard container.
Sample Stability at Room Temperature: 4 hours
Sample Stability at Refrigeration: 48 hours
Sample Stability at Frozen: 1 month
Medical History: Document heart disease risk or developmental delay. Include current medications or diet.
Consent: Written consent required, detailing the test's purpose, disease risks (e.g., stroke), and sample collection risks.
Procedural Considerations: Uses LC-MS/MS to measure homocystine, requiring labs with mass spectrometers. Results available in 2-3 days. Performed in labs with strict handling.
Factors Affecting Result Accuracy: Non-fasting status or sample hemolysis can affect results. Medications may alter levels, requiring correlation.
Clinical Significance: Elevated homocystine confirms homocystinuria or risk, guiding therapy. Early treatment might prevent complications, while untreated cases lead to death. Normal levels may require urine testing.
Specialist Consultation: Consult a cardiologist or metabolic specialist for interpretation.
Additional Supporting Tests: Urine homocystine, methionine levels, or genetic panel to confirm diagnosis.
Test Limitations: Non-specific for cause; correlation with symptoms needed. False negatives possible with low levels.
References: AHA Guidelines, 2023; Journal of Clinical Investigation, Carson NA, 2022.
